Skip to main content
SpringerLink
Log in

Benigne Nierentumoren

  • Chapter
Book cover Facharztwissen Urologie

  • 2500 Accesses

Zusammenfassung

  • Angiomyolipome (AML) werden zu 0,3% im Sektionsgut und zu 0,13% in Screening- analysen per Ultraschall beschrieben, 50% der AML heute inzidentell,

  • 20–30% der AML werden bei Patienten mit TS nachgewiesen, durchschnittliches Alter dieser Patienten ca. 30 Jahre (familiäre und hereditäre Formen der TS sind häufig assoziiert mit mentaler Retardierung, Epilepsie, Fettgewebetumoren),

  • 70–80% der Patienten mit einem AML haben keine tuberöse Sklerose (TS), Altersgipfel in diesem Patientenkollektiv in der 6. Dekade,

  • gelegentlich mit Angiomyolipomen in Gehirn, Lunge, Augen und Knochen vergesellschaftet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

16.3 Literatur

  • Arbeitsgemeinschaft der wissenschaftlichen Medizinischen Fachgesellschaften/AWMF (2000) Interdisziplinäre kurzgefaßte Leitlinien der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Urologie. Nierenzellkarzinom. AWMF-Leitlinien-Register Nr. 032/037, 2000, A25 331 ff.

    Google Scholar 

  • Bonsib SM, Gibson D, Mhoon M, Greene GF (2000) Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24:451–458

    Article  CAS  PubMed  Google Scholar 

  • Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57:339–344

    Article  CAS  PubMed  Google Scholar 

  • Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2 b compared with interferon alfa-2 b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659

    Article  CAS  PubMed  Google Scholar 

  • Gleave ME, Elhilali M, Fradet Y et al. (1998) Interferon gamma-1 b compared with placebo in metastatic renalcell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271

    Article  CAS  PubMed  Google Scholar 

  • Hafez KS, Fergany AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162:1930–1933

    Article  CAS  PubMed  Google Scholar 

  • Maher ER, Yates JR, Harries R, Benjamin C et al. (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–11–63

    CAS  PubMed  Google Scholar 

  • Maher ER, Webster AR, Moore AT (1995) Clinical features and molecular genetics of Von Hippel-Lindau disease. Ophthalmic Genet 16:79–84

    Article  CAS  PubMed  Google Scholar 

  • Matson MA, Cohen EP (1990) Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 69:217–226

    CAS  Google Scholar 

  • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970

    Article  CAS  PubMed  Google Scholar 

  • Pomer S, Klopp M, Steiner HH, Brkovic D, Staehler G, Cabillin-Engenhart R (1997) Brain metastases in renal cell carcinoma. Results of treatment and prognosis. Urologe (A) 36:117–125

    Article  CAS  Google Scholar 

  • Riese W, Goldenberg K, Freytag A (1998) Spontanremissionen und deren Einfluß auf die Prognose von Patienten mit metastasiertem Nierenzellkarzinom. In: Heim M, Schwarz R (Hrsg) Spontanremissionen in der Onkologie. Schattauer, Stuttgart, S 223–240

    Google Scholar 

  • Schlichter A, Wunderlich H, Junker K, Kosmehl H, Zermann DH, Schubert J (2000) Where are the limits of elective nephron-sparing surgery in renal cell carcinoma? Eur Urol 37:517–520

    Article  CAS  PubMed  Google Scholar 

  • Wittekind CH, Meyer HJ (2010) TNM. Klassifikation maligner Tumoren. Wiley-Blackwell

    Google Scholar 

  • Retz M, Gschwend J (2009) MedikamentöseTumortherapie in der Uroonkologie. Springer, Heidelberg

    Book  Google Scholar 

  • Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (2006) Campbell Walsh Urology Edition. Elsevier Health Sciences

    Google Scholar 

  • Dechet CB, Zincke H, Sebo TJ et al. (2003) Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol;169: 71–74

    Article  PubMed  Google Scholar 

  • Minor LD, Picken MM, Campbell SC et al. (2003) Benign renal tumors. AUA Update 22:170–175

    Google Scholar 

  • Motzer RJ, Hutson T, Tomczak P et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271–2281

    Google Scholar 

  • Escudier B, Eisen T, Stadler WM et al.; the TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125–134

    Article  CAS  PubMed  Google Scholar 

  • Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. Jan 25;(1): CD001425

    Google Scholar 

  • Ljungberg B, Hanbury DC, Kuczyk MA, et al.; European Association of Urology Guideline Group for renal cell carcinoma (2009) Renal cell carcinoma guideline. http://www.uroweb.org/nc/professional-resources/guidelines/online

  • Volpe A, Panzarella T, Rendon RA et al. (2004) The natural history of incidentally detected small renal masses. Cancer 15:738–745

    Article  Google Scholar 

  • Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW (2008) Percutaneous renal cryoablation: experience treating 115 tumors. J Urol 179(6): 2136–40

    Article  PubMed  Google Scholar 

  • Klingler HC (2007) Kidney cancer: energy ablation. Curr Opin Urol 17(5): 322–6, Review

    Article  PubMed  Google Scholar 

  • Rini BI, Halabi S, Rosenberg JE et al. (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol 26(33): 5422–8

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gemeinschaftspraxis für Urologie, Lübeckerstr. 18-20, 23611, Bad Schwartau, Germany

    V. Rohde (Dr. med.)

Authors
  1. V. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Rohde, V. (2010). Benigne Nierentumoren. In: Facharztwissen Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01626-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01626-4_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01625-7

  • Online ISBN: 978-3-642-01626-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation